Skip to main content


Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology

Fig. 1

CSF soluble PDGFRβ level is increased in Alzheimer’s disease (AD) in relation to CSF markers of BBB leakiness (CSF albumin) and disease pathology (elevated total tau (t-tau) and phosphorylated tau (p-tau)). a Dot plot showing significantly higher levels of CSF sPDGFRβ in AD compared to controls (n = 39 per group) (p = 0.0038). b Dot plot showing CSF albumin level in the AD and controls (p = 0.18). c Scatterplots showing positive correlation between CSF sPDGFRβ and CSF albumin in AD. df Scatterplots showing a positive correlation between CSF sPDGFRβ and t-tau and p-tau but not with Aβ42 in AD. In a and b, the bars represent the mean ± SEM. In cf, the best-fit linear regression line is shown and 95% confidence intervals are superimposed. Each dot represents an individual sample. p < 0.05 was considered statistically significant

Back to article page